Diagnosing pancreatic cancer early remains one of the greatest challenges in medicine, as the disease often shows no symptoms until it has progressed significantly. Understanding who should seek testing, which methods doctors use to identify the cancer, and how clinical trials establish qualification criteria can help patients and their families navigate this difficult journey.

Introduction: Who Should Undergo Diagnostics

Pancreatic cancer is notoriously difficult to detect in its early stages. Most people do not experience noticeable symptoms until the disease has already spread to other parts of the body. This means that by the time many patients feel unwell enough to see a doctor, the cancer is often at an advanced stage. In fact, around 80% of people diagnosed with pancreatic cancer present with disease that has already spread beyond the pancreas or grown into surrounding tissues.^[13]

Anyone experiencing persistent symptoms should seek medical attention promptly. Common warning signs include yellowing of the skin and eyes, a condition known as jaundice, which occurs when a tumor blocks the bile duct. Other symptoms include ongoing pain in the upper abdomen or middle back, unexplained weight loss, extreme tiredness, changes in stool color (particularly light-colored stools), dark urine, loss of appetite, nausea, and digestive problems.^[1][2][4]

Healthcare providers might suspect pancreatic cancer if someone develops new-onset diabetes, particularly if it appears suddenly in an older adult without obvious risk factors. Similarly, a painful condition called pancreatitis—inflammation of the pancreas—may prompt doctors to investigate further, especially if it occurs without a clear cause like gallstones or alcohol use.^[2]

Certain individuals face higher risks and should be particularly attentive to symptoms. People who smoke, those over 55 years old, individuals with long-standing diabetes, those with chronic pancreatitis, and people with a family history of pancreatic cancer should discuss screening options with their doctors. Additionally, those with certain inherited conditions, such as hereditary breast and ovarian cancer syndrome, Lynch syndrome, Peutz-Jeghers syndrome, or familial atypical multiple mole melanoma syndrome, have increased risk and may benefit from earlier or more frequent monitoring.^[4][5]

Diagnostic Methods

Diagnosing pancreatic cancer involves multiple steps and various types of tests. Because the pancreas sits deep in the abdomen, tucked behind the stomach and in front of the spine, doctors cannot see or feel tumors during routine physical examinations. This hidden location makes imaging and laboratory tests essential for detection.^[2][11]

Physical Examination and Medical History

The diagnostic process typically begins with a thorough physical examination and discussion of medical history. Your doctor will ask about symptoms, how long they have been present, family history of cancer, smoking habits, and other risk factors. During the physical exam, the doctor may feel the abdomen for lumps or fluid buildup and check for jaundice by examining the skin and eyes.^[10]

Blood Tests

Blood tests play an important role in diagnosis, though no single blood test can definitively confirm pancreatic cancer. Doctors often check liver function tests, which may show abnormal results if a tumor is blocking bile ducts. A test called CA 19-9 measures a protein that can be elevated in people with pancreatic cancer. However, this marker is not perfect—some people with pancreatic cancer have normal CA 19-9 levels, and the protein can also be elevated in other conditions. Therefore, CA 19-9 is most useful for monitoring treatment response rather than initial diagnosis.^[10]

Additional blood tests may check for elevated levels of enzymes called amylase and glucagon, or assess blood sugar levels, since pancreatic cancer can affect insulin production and lead to diabetes.^[10]

Imaging Tests

Imaging tests are crucial for visualizing the pancreas and detecting tumors. Several different imaging techniques are commonly used in pancreatic cancer diagnosis.

Computed Tomography (CT) scans are among the most important imaging tools. These scans use X-rays taken from multiple angles to create detailed, three-dimensional images of the pancreas and surrounding organs. CT scans help doctors determine the size and location of a tumor, whether it has spread to nearby blood vessels or other organs, and whether it might be removable through surgery. A special type called a pancreatic protocol CT scan is specifically designed to evaluate pancreatic abnormalities.^[10]

Magnetic Resonance Imaging (MRI) uses magnets and radio waves instead of radiation to create detailed pictures of soft tissues. MRI is particularly useful for examining the pancreas and can sometimes detect small tumors that CT scans miss. A specialized MRI technique called magnetic resonance cholangiopancreatography (MRCP) can show the bile ducts and pancreatic ducts in detail without requiring invasive procedures.^[10]

Ultrasound uses sound waves to create images of internal organs. Traditional abdominal ultrasound can sometimes detect pancreatic tumors, but the pancreas’s deep location often makes visualization difficult. However, a more advanced technique called endoscopic ultrasound (EUS) provides much clearer images. During EUS, a thin, flexible tube with an ultrasound probe on the end is passed down the throat, through the stomach, and into the small intestine, bringing the probe very close to the pancreas. This allows for highly detailed imaging and also enables doctors to take tissue samples through needle biopsy during the same procedure.^[10]

Positron Emission Tomography (PET) scans involve injecting a small amount of radioactive sugar into the bloodstream. Cancer cells, which consume more sugar than normal cells, show up as bright spots on the scan. PET scans are particularly useful for determining if cancer has spread to other parts of the body.^[10]

Endoscopic Procedures

Endoscopic techniques allow doctors to look inside the digestive system and obtain tissue samples. Endoscopic Retrograde Cholangiopancreatography (ERCP) combines endoscopy with X-ray imaging. A flexible tube is passed through the mouth, down through the stomach, and into the small intestine. A smaller tube is then threaded through the endoscope into the bile and pancreatic ducts. Dye is injected to make these ducts visible on X-rays, helping identify blockages or abnormalities. ERCP can also be used to place stents—small tubes that help keep blocked ducts open.^[10]

Biopsy

A biopsy—removing a small piece of tissue for examination under a microscope—is the only way to definitively confirm pancreatic cancer. Several biopsy techniques are available. Fine needle aspiration, often performed during endoscopic ultrasound, uses a thin needle to extract cells from the suspicious area. Alternatively, biopsies can be performed through the skin using imaging guidance, a technique called percutaneous biopsy. In some cases, tissue samples are obtained during surgical exploration.^[10]

The tissue sample is examined by a specialist called a pathologist, who determines whether cancer cells are present, what type of pancreatic cancer it is, and how aggressive the cells appear. This information, called histologic findings, is essential for treatment planning.^[10]

Staging

Once pancreatic cancer is confirmed, doctors determine its stage—how far the disease has spread. Staging combines information from imaging tests, biopsies, and sometimes surgical exploration. Pancreatic cancer is typically classified as resectable (can be removed by surgery), borderline resectable (might be removable with treatment first), locally advanced (has grown into nearby structures but not spread distantly), or metastatic (has spread to distant organs). Understanding the stage is critical because it guides treatment decisions.^[10][15]

Genetic Testing and Molecular Analysis

Increasingly, doctors recommend genetic testing for patients diagnosed with pancreatic cancer. This involves analyzing the tumor tissue and sometimes the patient’s blood to look for specific genetic mutations. About 10% of pancreatic cancers are linked to inherited genetic changes. Identifying these mutations is important not only for the patient’s treatment options but also because family members might benefit from genetic counseling and increased surveillance. Certain genetic mutations, such as BRCA genes, may make patients eligible for specific targeted therapies.^[10]

Diagnostics for Clinical Trial Qualification

Clinical trials test new treatments and approaches to improve outcomes for pancreatic cancer patients. Patients who participate in clinical trials often have better outcomes than those who receive only standard treatments. Every treatment available today was approved through clinical trials, making participation an important consideration at diagnosis and throughout treatment.^[8]

To enroll in a clinical trial, patients must meet specific qualification criteria, often called eligibility criteria. These requirements ensure that the study tests the treatment in the appropriate patient population and that participants are likely to tolerate the experimental therapy safely. Diagnostic tests play a central role in determining eligibility.^[10]

Standard Diagnostic Requirements

Most pancreatic cancer clinical trials require confirmation of the diagnosis through biopsy and pathology review. The tumor type must be verified—most trials focus on the most common type, called pancreatic ductal adenocarcinoma, which accounts for about 95% of pancreatic cancers. Trials studying rarer types, such as neuroendocrine tumors, have separate enrollment criteria.^[4][11]

Staging information is crucial for trial eligibility. Some trials enroll only patients with resectable disease, others focus on locally advanced or metastatic cancer, and still others include patients across multiple stages. Detailed imaging—typically including CT scans and sometimes MRI or PET scans—is required to accurately determine disease extent and ensure patients meet the trial’s staging criteria.^[10]

Performance Status Assessment

Clinical trials assess patients’ overall health and ability to perform daily activities, measured through something called performance status. Doctors use standardized scales to rate how well patients function. This assessment helps ensure that patients can safely tolerate the experimental treatment. Patients who are very weak or unable to care for themselves may not qualify for trials testing aggressive therapies, though trials specifically designed for patients with lower performance status do exist.^[15]

Laboratory Test Requirements

Blood tests are standard requirements for clinical trial enrollment. Trials typically require adequate organ function, verified through laboratory measurements. Blood cell counts must meet minimum thresholds to ensure patients can tolerate chemotherapy or other treatments. Kidney and liver function tests must fall within acceptable ranges. These laboratory requirements protect patient safety by excluding individuals whose organs might not handle the experimental treatment well.^[10]

Biomarker and Genetic Testing

Many modern clinical trials require specific biomarker or genetic testing before enrollment. Biomarkers are measurable substances in the body that indicate disease characteristics. For pancreatic cancer, tumor tissue may be tested for genetic mutations, protein expression patterns, or other molecular features. Some trials enroll only patients whose tumors have specific genetic changes, while others may exclude patients with certain mutations.^[10]

For example, trials testing drugs called PARP inhibitors typically require testing for BRCA mutations. Tumors may also be tested for changes in genes like KRAS, which is mutated in most pancreatic cancers, or for a characteristic called microsatellite instability. These molecular tests help match patients to treatments most likely to benefit them.^[10]

Imaging for Trial Monitoring

Beyond initial qualification, clinical trials use diagnostic imaging throughout treatment to monitor how tumors respond to therapy. Standardized measurement techniques, often following guidelines called RECIST criteria, track changes in tumor size. Regular CT or MRI scans at predetermined intervals document whether tumors are shrinking, staying stable, or growing. These imaging studies generate the data that ultimately determines whether new treatments work.^[10]

Quality of Life Assessments

Many clinical trials incorporate standardized questionnaires and assessments to measure how treatments affect patients’ daily lives, symptoms, and emotional well-being. While not diagnostic tests in the traditional sense, these quality-of-life assessments are important qualification and monitoring tools in modern trials, recognizing that effective cancer treatment must consider the whole person, not just tumor response.^[10]